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Left atrial appendage (LAA) thrombosis is an important cause of cardiogenic cerebral thromboembolism. Apixaban
is a member of the class of novel oral anticoagulants (NOAC) and is superior to warfarin in preventing stroke or
systemic embolism, causes less bleeding, and results in lower mortality in patients with atrial fibrillation. There are
few reports of resolution of LAA thrombus with other NOAC. We present a 72-year-old male patient with persistent
atrial fibrillation associated with left atrial thrombus. Sixteen days of apixaban treatment showed complete thrombus
resolution. In this study, soluble fibrin and D-dimer levels decreased without prolongation of international normalized
ratio (INR) and activated partial thromboplastin time (APTT).
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Left atrial appendage (LAA) thrombus is commonly as-
sociated with atrial fibrillation (AF) and causes thrombo-
embolic complications. Warfarin is used for prevention
of thromboembolic complications with AF patients and
resolution of LAA thrombus [1]. Apixaban is a member
of the class of novel oral anticoagulants (NOAC). It is
superior to warfarin in preventing stroke or systemic
embolism, and causes less bleeding [2]. Few reports exist
detailing resolution of LAA thrombus with other novel
oral anticoagulants (NOAC) [3,4].Case presentation
A 72-year-old male consulted our hospital due to dyspnea
and palpitation, maintained for one week or more. On
hospital admission the patient presented with functional
NYHA class III; he had a clinical history of non-ischemic
cardiomyopathy with severely impaired left ventricular
function and a moderate AF-related thromboembolic risk
with an actual CHA2DS2VASc score of 3, and had not
been pretreated with anticoagulant. We determined that
he required rapid anticoagulation to be delivered orally.
We started oral anticoagulation (OAC) therapy with the
direct factor Xa (FXa) inhibitor apixaban (5 mg twice
daily). The patient had high levels of soluble fibrin (SF)* Correspondence: tkawakami-ind@umin.ac.jp
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stated.and D-dimer, normal levels of international normalized
ratio (INR) and activated partial thromboplastin time
(APTT) on hospitalization. We performed transesophageal
echocardiography (TEE), which revealed formation of a
small thrombus (11 × 10 mm) in the left atrial appendage
(LAA) (Figure 1A). After 16 days of apixaban treatment
TEE showed complete thrombus resolution (Figure 1B).
During apixaban treatment SF and D-dimer changed
as the day passed; SF fell, while there was a rise and
subsequent fall in D-dimer, without prolongation of INR
or APTT (Figure 1C).
Finally, catheter ablation of persistent AF was performed
successfully without clinical signs of cardiac embolism
after 22 days of apixaban treatment and the patient was
discharged in good medical condition under continued
anticoagulant treatment with apixaban.
In this study we collected blood samples before break-
fast. INR, PT, APTT, SF, and D-dimer were detectable
in this trough period. All assays were performed in the
laboratory of our institute. For quantitative determination
of coagulation systems an automated coagulation analyzer
was used (Coapresta 2000: Sekisui Medical Co., Ltd.,
Tokyo, Japan). PT was measured with Coagpia PT-N,
whose international sensitivity index is almost equal to
1.0 (Sekisui Medical Co., Ltd.). APTT was measured
with Coagpia APTT-N (Sekisui Medical Co., Ltd.). SF
in sodium citrate plasma was measured with Nanopia
SF (Sekisui Medical Co., Ltd.). D-dimer in sodium citrateral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited. The Creative Commons Public Domain Dedication
ain/zero/1.0/) applies to the data made available in this article, unless otherwise
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Figure 1 Transesophageal echocardiography and laboratory data for the coagulation system. A) Small thrombus formation (arrow) in the
apex of the left atrial appendage (LAA) on day 4. B) Thrombus resolution after 16 days of anticoagulant therapy with apixaban. C) Plot of
laboratory data for the coagulation system demonstrates a fall in SF, a rise and subsequent fall in D-dimer (DD), without prolongation of INR
or APTT.
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Medical Co., Ltd.). Processing and analyses were performed
within 90 minutes of sample collection.
Discussion
Apixaban is superior to warfarin in preventing stroke
or systemic embolism, caused less bleeding, and resulted
in lower mortality in patients with atrial fibrillation [2].
Resolution of LAA thrombus with warfarin has been pre-
viously reported [5]. There have been a few cases outlining
resolution of LAA thrombus with other NOAC [3,4].
To our knowledge this is the first documented case
of LAA thrombus resolution under apixaban therapy
and demonstrates the changes in laboratory data for
the coagulation system. The optimal therapeutic range
for anticoagulation with warfarin in the prevention of
thromboembolic events with non-valvular AF patients
extends over INR values of 2.0 to 3.0 [6,7]. It has beenreported that major bleeding is observed only at INR
values above 2.5 on anticoagulation with warfarin [1].
In this study, SF and D-dimer levels decreased without
prolongation of INR and APTT.
Recently, SF and D-dimer levels have been considered
useful for diagnosis of thrombosis [8-14]. The TEE-guided
approach with short-term anticoagulation is considered
to be as safe and clinically effective as the conventional
approach, and is advocated in patients in whom earlier
cardioversion would be clinically beneficial [8,15,16].
Addition of the TEE-guided approach to monitoring of
fibrin-related markers such as SF and D-dimer may be
safer than the simple TEE-guided approach for rhythm
control strategy in AF patients.
Apixaban treatment enabled thrombus resolution within
a manageable time period. Therefore, this NOAC could be
considered to have an important role in rhythm control
strategies in similar cases. It is of undoubted interest and
requires further investigation in a larger population.
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dabigatran treatment, which is associated with dyspepsia.
Furthermore, rivaroxaban treatment was not powered for
efficacy in the J-ROKET-AF study [17].
Conclusions
We report LAA thrombus resolution with apixaban. In
this study, SF and D-dimer levels decreased along with
LAA thrombus resolution without prolongation of INR
and APTT.
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